Company / SG&A Expense
Atea Pharmaceuticals, Inc. SG&A Expense History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$48.7M
FY2022
5-year range
$2.8M / $48.7M
FY2020-FY2022
Trend
+997.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense changed +998% YoY in FY2022, a notable deviation from the 2-year average annual change of +528%.
Based on SEC 10-K filings.
$49M in FY2022.
Increased from $3M to $49M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, sg&a expense increased 997.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $48.7M | +997.7% |
| FY2021 | $4.4M | +58.4% |
| FY2020 | $2.8M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026